Nurix Therapeutics (NRIX) Competitors $8.44 -0.53 (-5.91%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$8.57 +0.13 (+1.54%) As of 09/19/2025 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NRIX vs. KNSA, NAMS, BHC, GMTX, CGON, MLYS, IBRX, CPRX, ALVO, and OCULShould you be buying Nurix Therapeutics stock or one of its competitors? The main competitors of Nurix Therapeutics include Kiniksa Pharmaceuticals International (KNSA), NewAmsterdam Pharma (NAMS), Bausch Health Cos (BHC), Gemini Therapeutics (GMTX), CG Oncology (CGON), Mineralys Therapeutics (MLYS), ImmunityBio (IBRX), Catalyst Pharmaceuticals (CPRX), Alvotech (ALVO), and Ocular Therapeutix (OCUL). These companies are all part of the "pharmaceutical products" industry. Nurix Therapeutics vs. Its Competitors Kiniksa Pharmaceuticals International NewAmsterdam Pharma Bausch Health Cos Gemini Therapeutics CG Oncology Mineralys Therapeutics ImmunityBio Catalyst Pharmaceuticals Alvotech Ocular Therapeutix Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Nurix Therapeutics (NASDAQ:NRIX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment. Which has higher earnings and valuation, KNSA or NRIX? Kiniksa Pharmaceuticals International has higher revenue and earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKiniksa Pharmaceuticals International$423.24M6.20-$43.19M$0.04885.50Nurix Therapeutics$54.55M11.83-$193.57M-$2.61-3.23 Do analysts rate KNSA or NRIX? Kiniksa Pharmaceuticals International currently has a consensus price target of $41.17, indicating a potential upside of 16.22%. Nurix Therapeutics has a consensus price target of $29.07, indicating a potential upside of 244.45%. Given Nurix Therapeutics' higher probable upside, analysts clearly believe Nurix Therapeutics is more favorable than Kiniksa Pharmaceuticals International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiniksa Pharmaceuticals International 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Nurix Therapeutics 0 Sell rating(s) 3 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.88 Is KNSA or NRIX more profitable? Kiniksa Pharmaceuticals International has a net margin of 0.90% compared to Nurix Therapeutics' net margin of -234.57%. Kiniksa Pharmaceuticals International's return on equity of 1.05% beat Nurix Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kiniksa Pharmaceuticals International0.90% 1.05% 0.80% Nurix Therapeutics -234.57%-45.26%-34.71% Does the media refer more to KNSA or NRIX? In the previous week, Kiniksa Pharmaceuticals International had 2 more articles in the media than Nurix Therapeutics. MarketBeat recorded 7 mentions for Kiniksa Pharmaceuticals International and 5 mentions for Nurix Therapeutics. Kiniksa Pharmaceuticals International's average media sentiment score of 1.10 beat Nurix Therapeutics' score of 0.77 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kiniksa Pharmaceuticals International 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nurix Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in KNSA or NRIX? 54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 53.5% of Kiniksa Pharmaceuticals International shares are owned by company insiders. Comparatively, 7.4% of Nurix Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more volatility & risk, KNSA or NRIX? Kiniksa Pharmaceuticals International has a beta of 0.2, meaning that its stock price is 80% less volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 2.1, meaning that its stock price is 110% more volatile than the S&P 500. SummaryKiniksa Pharmaceuticals International beats Nurix Therapeutics on 12 of the 17 factors compared between the two stocks. Get Nurix Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRIX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NRIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRIX vs. The Competition Export to ExcelMetricNurix TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$685.75M$3.16B$5.79B$10.39BDividend YieldN/A2.37%5.63%4.60%P/E Ratio-3.2320.6576.5426.77Price / Sales11.83446.54531.65124.20Price / CashN/A46.0037.9261.55Price / Book1.139.6613.746.40Net Income-$193.57M-$53.02M$3.29B$271.62M7 Day Performance-6.64%3.11%2.65%3.46%1 Month Performance-11.44%7.56%6.03%9.89%1 Year Performance-67.06%11.15%80.13%28.51% Nurix Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRIXNurix Therapeutics2.0156 of 5 stars$8.44-5.9%$29.07+244.4%-66.3%$685.75M$54.55M-3.23300Positive NewsHigh Trading VolumeKNSAKiniksa Pharmaceuticals International2.7128 of 5 stars$36.56-1.5%$41.17+12.6%+34.9%$2.75B$423.24M914.23220Positive NewsInsider TradeShort Interest ↑NAMSNewAmsterdam Pharma3.1195 of 5 stars$24.12-0.3%$41.55+72.2%+66.2%$2.72B$45.56M-14.894Positive NewsBHCBausch Health Cos4.6802 of 5 stars$7.17-1.2%$9.00+25.5%-17.8%$2.69B$9.63B27.5820,700Analyst UpgradeGMTXGemini TherapeuticsN/A$59.82-0.8%N/A+28.9%$2.59BN/A-59.8230News CoverageCGONCG Oncology2.6115 of 5 stars$34.60+3.8%$53.91+55.8%-5.7%$2.54B$1.14M-19.5561Analyst ForecastAnalyst RevisionGap UpMLYSMineralys Therapeutics2.508 of 5 stars$36.21-2.4%$43.50+20.1%+224.5%$2.46BN/A-10.1728Insider TradeIBRXImmunityBio2.3435 of 5 stars$2.74+5.4%$10.75+292.3%-21.6%$2.46B$14.74M-5.71590High Trading VolumeCPRXCatalyst Pharmaceuticals4.948 of 5 stars$19.76-1.1%$33.20+68.0%-7.4%$2.44B$491.73M11.9880Positive NewsALVOAlvotech3.3616 of 5 stars$8.12+1.1%$14.00+72.4%-29.5%$2.42B$491.98M35.301,032News CoveragePositive NewsShort Interest ↓OCULOcular Therapeutix3.8868 of 5 stars$12.54-2.1%$17.83+42.2%+33.8%$2.23B$63.72M-9.80230Positive NewsGap Up Related Companies and Tools Related Companies KNSA Alternatives NAMS Alternatives BHC Alternatives GMTX Alternatives CGON Alternatives MLYS Alternatives IBRX Alternatives CPRX Alternatives ALVO Alternatives OCUL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NRIX) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nurix Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nurix Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
